Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Insulet Dives After Dexcom Says it is Not in Merger Discussions

Published 31/05/2022, 16:50
Updated 31/05/2022, 16:50
© Reuters.

© Reuters.

By Sam Boughedda

Shares of insulin delivery device maker Insulet (NASDAQ:PODD) have tumbled 12% in early trading Tuesday following a statement from Dexcom (NASDAQ:DXCM) regarding rumors of a potential acquisition of the company.

Last Monday, Bloomberg reported Dexcom was in discussions to acquire Insulet, citing people familiar with the matter.

Dexcom, a company that produces glucose monitoring systems for diabetes management, has now refuted the reports, stating they are not in any discussions regarding a merger.

The company said it regularly reviews opportunities to enhance stockholder value and create benefits for customers, and it does not usually comment on speculation.

However, Dexcom released a statement, stating: "In light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time."

Insulet shares hit a high of $238.60 in the days following Bloomberg's report but have dropped Tuesday, hitting a low of $199.56. Dexcom stock fell below $270 last week but is trading 6.5% higher in today's session.

Following Dexcom's press release, BTIG analyst Marie Thibault said, "DXCM shares had been pressured in the days following the Bloomberg report while PODD shares have surged. Shares have since reversed in pre-market trading and are near last Monday's close (Dexcom at $324.15 and PODD at $203.12). We expect shares to continue to be volatile in the coming days as investors digest this release ahead of this upcoming weekend's American Diabetes Association 82nd Scientific Sessions."

The analyst reiterated a Buy rating and a $540 price target on Dexcom.

Oppenheimer's Steven Lichtman is not surprised by the news, saying they questioned the fit. They see the companies benefiting from their connection through Omnipod 5 without having to be under one roof. Lichtman rates Dexcom at Outperform with a $525 target.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.